Financial reports
10-Q
2024 Q1
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
10-K
2023 FY
Annual report
28 Sep 23
10-Q
2023 Q3
Quarterly report
15 May 23
10-Q
2023 Q2
Quarterly report
15 Feb 23
NT 10-Q
Notice of late quarterly filing
15 Feb 23
10-Q
2023 Q1
Quarterly report
10 Nov 22
10-K
2022 FY
Annual report
28 Sep 22
10-Q
2022 Q3
Quarterly report
13 May 22
10-Q
2022 Q2
Quarterly report
14 Feb 22
Current reports
8-K
Departure of Directors or Certain Officers
1 Feb 24
8-K
Termination of a Material Definitive Agreement
5 Dec 23
8-K
Changes in Registrant's Certifying Accountant
30 Oct 23
8-K
Other Events
4 Jan 23
8-K
Entry into a Material Definitive Agreement
15 Jun 22
8-K
Departure of Directors or Certain Officers
14 Oct 21
8-K
Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives
15 Jan 21
8-K
FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ Brilacidin for Treating COVID-19
22 Dec 20
8-K
Entry into a Material Definitive Agreement
10 Dec 20
8-K
Innovation Pharmaceuticals Announces Overseas Regulatory Filing Submitted For COVID-19 Clinical Study
16 Nov 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
10 Dec 20
424B5
Prospectus supplement for primary offering
4 Aug 20
S-3
Shelf registration
10 Jul 20
424B3
Prospectus supplement
26 Dec 19
424B3
Prospectus supplement
16 Dec 19
POS AM
Prospectus update (post-effective amendment)
17 Oct 19
POS AM
Prospectus update (post-effective amendment)
20 Sep 19
424B5
Prospectus supplement for primary offering
10 May 19
424B5
Prospectus supplement for primary offering
9 Oct 18
424B5
Prospectus supplement for primary offering
29 Jun 18
Proxies
DEF 14A
Definitive proxy
13 Aug 19
PRE 14A
Preliminary proxy
2 Aug 19
DEFA14A
Additional proxy soliciting materials
2 Nov 15
DEF 14A
Definitive proxy
28 Oct 15
DEF 14C
Information statement
3 May 11
PRER14C
Preliminary revised information
31 Mar 11
PRER14C
Preliminary revised information
9 Mar 11
PRER14C
Preliminary revised information
22 Feb 11
PRE 14C
Preliminary information
8 Feb 11
DEF 14C
Information statement
28 Jan 08
Other
EFFECT
Notice of effectiveness
20 Jul 20
CORRESP
Correspondence with SEC
15 Jul 20
UPLOAD
Letter from SEC
15 Jul 20
EFFECT
Notice of effectiveness
22 Oct 19
EFFECT
Notice of effectiveness
21 Sep 17
CORRESP
Correspondence with SEC
19 Sep 17
UPLOAD
Letter from SEC
18 Sep 17
EFFECT
Notice of effectiveness
18 Nov 14
CORRESP
Correspondence with SEC
17 Nov 14
CORRESP
Correspondence with SEC
10 Nov 14
Ownership
4
LEO EHRLICH
4 Jan 23
4
Jane A. Harness
28 Sep 22
4
LEO EHRLICH
28 Sep 22
4
Zorik Spektor
28 Sep 22
4
Barry A Schechter
28 Sep 22
SC 13G/A
Kips Bay Select LP
5 Jul 22
SC 13G/A
Kips Bay Select LP
3 May 21
SC 13G
Kips Bay Select LP
11 Feb 21
SC 13G/A
Leviston Resources LLC
15 Jul 20
SC 13G
Leviston Resources LLC
10 Jul 20